Literature DB >> 24513268

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Tove Kirkegaard1, Susanne K Hansen2, Sarah L Larsen2, Birgit E Reiter2, Boe S Sørensen3, Anne E Lykkesfeldt2.   

Abstract

In this study, T47D cell lines resistant to the antiestrogen fulvestrant were established and analyzed to explore, whether a switch to HER signaling, as seen in fulvestrant resistant MCF-7 cell lines, is a general resistance mechanism. We find that parental T47D cells depend on ER and HER signaling for growth. Fulvestrant resistant T47D cells have lost ER expression and, although HER2 was over expressed, growth was only partially driven by HER receptors. Instead c-Src was important for resistant growth. Thus, the T47D and MCF-7 model system unravel different resistance mechanisms which may be important for fulvestrant resistant breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24513268     DOI: 10.1016/j.canlet.2013.10.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Authors:  Gladys Morrison; Xiaoyong Fu; Martin Shea; Sarmistha Nanda; Mario Giuliano; Tao Wang; Teresa Klinowska; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2014-02-20       Impact factor: 4.872

Review 2.  Role of ER-α36 in breast cancer by typical xenoestrogens.

Authors:  Jun Liu; Zhixiang Xu; Xiaodong Ma; Bin Huang; Xuejun Pan
Journal:  Tumour Biol       Date:  2015-09-04

3.  High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.

Authors:  Elpetra P M Timmermans-Sprang; Ana Gracanin; Jan A Mol
Journal:  BMC Cancer       Date:  2015-07-25       Impact factor: 4.430

4.  SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Authors:  Sarah L Larsen; Anne-Vibeke Laenkholm; Anne Katrine Duun-Henriksen; Martin Bak; Anne E Lykkesfeldt; Tove Kirkegaard
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

5.  Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Authors:  Sarah L Larsen; Christina W Yde; Anne-Vibeke Laenkholm; Birgitte B Rasmussen; Anne Katrine Duun-Henriksen; Martin Bak; Anne E Lykkesfeldt; Tove Kirkegaard
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

6.  Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Authors:  Amit Agrawal; John F R Robertson; Kwok L Cheung; Eleanor Gutteridge; Ian O Ellis; Robert I Nicholson; Julia M W Gee
Journal:  Int J Cancer       Date:  2015-07-30       Impact factor: 7.396

7.  Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis.

Authors:  Benjamin Leyh; Angela Dittmer; Theresia Lange; John W M Martens; Jürgen Dittmer
Journal:  Oncotarget       Date:  2015-11-17

8.  HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells.

Authors:  Jingchao Bai; Guanglin Zhou; Yufan Qiu; Yunhui Hu; Jingjing Liu; Jing Zhao; Sheng Zhang; Jin Zhang
Journal:  Cancer Sci       Date:  2017-05-19       Impact factor: 6.716

9.  Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.

Authors:  Rugaia Z Montaser; Helen M Coley
Journal:  Cancers (Basel)       Date:  2018-06-20       Impact factor: 6.639

10.  Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response.

Authors:  Norbert Nass; Angela Dittmer; Vicky Hellwig; Theresia Lange; Johanna Mirjam Beyer; Benjamin Leyh; Atanas Ignatov; Christine Weiβenborn; Tove Kirkegaard; Anne E Lykkesfeldt; Thomas Kalinski; Jürgen Dittmer
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.